- Posted September 9, 2013 - The National Pregnancy Registry for Atypical Antipsychotics For pregnant women between the ages of 18 and 45 and are currently treated with one or more of the following atypical antipsychotics:
This study will involve 3 brief phone interviews over an 8-month period. The National Pregnancy Registry for Atypical Antipsychotics is dedicated to evaluating the safety of atypical antipsychotic medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics during pregnancy. To register or for more information, please call 1-866-961-2388.
- Posted September 9, 2013 – Symptom Tracking in Assisted Reproductive Technologie (START Study) Are you planning infertility treatment? Do you have a history of depression or bipolar disorder? You may be eligible for a research study at the Center for Women’s Mental Health at Massachusetts General Hospital. We are conducting a study of the course of mood throughout infertility treatment cycles. This is an observational study that tracks women’s mood symptoms over a period of six months. Study participation includes monthly visits to the Center for Women’s Mental Health and infertility treatment diaries to be completed at home. The study has been tailored to meet the needs of the individual participant and can also be completed remotely for those women who do not live locally or who are unable to commit to clinic visits. Those eligible for the study include all women with a history of major depression or bipolar depression currently in remission who are planning or are under going infertility treatment. For more information, please call Shannon Murphy at 617-643-5154 or e-mail email@example.com. *If you are interested in participating in the START Study and would like to be contacted by our research coordinator, you can also submit your contact information using our patient interest form. All information is kept strictly confidential.
- Posted August 28, 2013 - The STEADi clinical research study for adolescents with major depressive disorder (MDD) The purpose of the STEADi (Study To Evaluate an Adolescent Depression Investigational drug) clinical research study is to find out if an investigational drug is safe and to see if it works for adolescents who have MDD. Girls and boys who are 12 to 17 years old and have been diagnosed with MDD or who have been feeling depressed for at least the past 6 weeks may be eligible to participate in the study. The study will last for about 10 weeks. A parent or consenting caregiver will need to come with your child to the study doctor’s office about 9 times. About 500 adolescents will take part in the study, which is being done at about 60 study centers across the United States. To see if your child may qualify, visit www.steadiresearchstudy.com or call 877-900-8735.
- Posted July 18, 2013 -Eszopiclone for the Treatment of PTSD The purpose of this study is to determine if a hypnotic, eszopiclone (Lunesta®), is effective for patients who have or may have PTSD and sleep disturbance. Participants will receive 12 weeks of eszopiclone or placebo and be evaluated for changes in their sleep and PTSD symptoms. Participants must be 17-65 years of age and be in good physical health. Concomitant antidepressants are allowed if on a stable dose for at least 6 weeks. Participants must discontinue other psychotropics including benzodiazepines, antipsychotics, and hypnotics at least two weeks prior to receiving study drug. All study-related procedures, psychiatric evaluation, and medication are free. Patients will be reimbursed for their travel expenses at each visit. Contact: Jennifer N. Baumgartner, Research coordinator312-563-6687 Jennifer_Baumgartner@rush.edu
- Posted July 8, 2013 – Bipolar Adjunctive Therapy with N-Acetyl Cysteine and Aspirin We are currently recruiting men and women between the ages of 18-65 who are currently suffering from BP I or BP II disorder and receiving treatment with a mood stabilizer. Patients would continue current treatment while taking study medication. Patients may be compensated for their participation in the 16 week study. Please contact us at 713-486-2627 or firstname.lastname@example.org . Or visit our website at utmooddisorders.org
- Posted July 8, 2013 – Bipolar Disorder Sibling Neuroimaging Study We are currently recruiting men and women between the ages of 18-65 who suffer from Bipolar Disorder I and have a same-sex sibling who does not suffer from BP disorder. The study consists of interview, MRI, and neuropsychological testing. You and your sibling will receive $300 each for completing the study. Please contact us at 713-486-2627 or email@example.com . Or visit our website at utmooddisorders.org
- Posted July 1, 2013 - The Charles E. Schmidt College of Medicine at Florida Atlantic University in Boca Raton, FL specializes in dementia clinical trials. We are currently recruiting subjects with mild cognitive impairment (MCI) due to Alzheimer’s disease or mild Alzheimer’s disease. For more information, please contact 561-297-0164. http://www.clinicaltrials.gov/ct2/show/study/NCT01767311
- Posted July 1, 2013 - The clinical trial is a Phase II double-blind placebo-controlled 6-week trial of the CRF1 antagonist GSK561679 for women with PTSD. Women aged 18-65 who are not pregnant or nursing and are medically healthy may be eligible. The clinical trial sites include Emory School of Medicine, Atlanta, GA; Mount Sinai School of Medicine, New York, NY; Baylor College of Medicine, Houston, TX; and San Francisco VA Medical Center, San Francisco, CA. For more information, visit: http://clinicaltrials.gov/ct2/show/NCT01018992?term=crf1&rank=3